An Overview of MicroRNAs as Biomarkers of ALS
Amyotrophic lateral sclerosis (ALS; MND, motor neuron disease) is a debilitating neurodegenerative disease affecting 4.5 per 100,000 people per year around the world. There is currently no cure for this disease, and its causes are relatively unknown. Diagnosis is based on a battery of clinical tests...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-03-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00186/full |
| _version_ | 1819071808163282944 |
|---|---|
| author | Greig Joilin P. Nigel Leigh Sarah F. Newbury Majid Hafezparast |
| author_facet | Greig Joilin P. Nigel Leigh Sarah F. Newbury Majid Hafezparast |
| author_sort | Greig Joilin |
| collection | DOAJ |
| description | Amyotrophic lateral sclerosis (ALS; MND, motor neuron disease) is a debilitating neurodegenerative disease affecting 4.5 per 100,000 people per year around the world. There is currently no cure for this disease, and its causes are relatively unknown. Diagnosis is based on a battery of clinical tests up to a year after symptom onset, with no robust markers of diagnosis or disease progression currently identified. A major thrust of current research is to identify potential non-invasive markers (“biomarkers”) in body fluids such as blood and/or cerebrospinal fluid (CSF) to use for diagnostic or prognostic purposes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), are found at detectable and stable levels in blood and other bodily fluids. Specific ncRNAs can vary in levels between ALS patients and non-ALS controls without the disease. In this review, we will provide an overview of early findings, demonstrate the potential of this new class as biomarkers, and discuss future challenges and opportunities taking this forward to help patients with ALS. |
| first_indexed | 2024-12-21T17:27:43Z |
| format | Article |
| id | doaj.art-05651055ae9f48c998ac7956002e306e |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-21T17:27:43Z |
| publishDate | 2019-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-05651055ae9f48c998ac7956002e306e2022-12-21T18:56:01ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-03-011010.3389/fneur.2019.00186435397An Overview of MicroRNAs as Biomarkers of ALSGreig Joilin0P. Nigel Leigh1Sarah F. Newbury2Majid Hafezparast3School of Life Sciences, University of Sussex, Brighton, United KingdomBrighton and Sussex Medical School, University of Sussex, Brighton, United KingdomBrighton and Sussex Medical School, University of Sussex, Brighton, United KingdomSchool of Life Sciences, University of Sussex, Brighton, United KingdomAmyotrophic lateral sclerosis (ALS; MND, motor neuron disease) is a debilitating neurodegenerative disease affecting 4.5 per 100,000 people per year around the world. There is currently no cure for this disease, and its causes are relatively unknown. Diagnosis is based on a battery of clinical tests up to a year after symptom onset, with no robust markers of diagnosis or disease progression currently identified. A major thrust of current research is to identify potential non-invasive markers (“biomarkers”) in body fluids such as blood and/or cerebrospinal fluid (CSF) to use for diagnostic or prognostic purposes. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), are found at detectable and stable levels in blood and other bodily fluids. Specific ncRNAs can vary in levels between ALS patients and non-ALS controls without the disease. In this review, we will provide an overview of early findings, demonstrate the potential of this new class as biomarkers, and discuss future challenges and opportunities taking this forward to help patients with ALS.https://www.frontiersin.org/article/10.3389/fneur.2019.00186/fullamyotrophic lateral sclerosismotor neuron diseasebiomarkersnon-coding RNAmicroRNA |
| spellingShingle | Greig Joilin P. Nigel Leigh Sarah F. Newbury Majid Hafezparast An Overview of MicroRNAs as Biomarkers of ALS Frontiers in Neurology amyotrophic lateral sclerosis motor neuron disease biomarkers non-coding RNA microRNA |
| title | An Overview of MicroRNAs as Biomarkers of ALS |
| title_full | An Overview of MicroRNAs as Biomarkers of ALS |
| title_fullStr | An Overview of MicroRNAs as Biomarkers of ALS |
| title_full_unstemmed | An Overview of MicroRNAs as Biomarkers of ALS |
| title_short | An Overview of MicroRNAs as Biomarkers of ALS |
| title_sort | overview of micrornas as biomarkers of als |
| topic | amyotrophic lateral sclerosis motor neuron disease biomarkers non-coding RNA microRNA |
| url | https://www.frontiersin.org/article/10.3389/fneur.2019.00186/full |
| work_keys_str_mv | AT greigjoilin anoverviewofmicrornasasbiomarkersofals AT pnigelleigh anoverviewofmicrornasasbiomarkersofals AT sarahfnewbury anoverviewofmicrornasasbiomarkersofals AT majidhafezparast anoverviewofmicrornasasbiomarkersofals AT greigjoilin overviewofmicrornasasbiomarkersofals AT pnigelleigh overviewofmicrornasasbiomarkersofals AT sarahfnewbury overviewofmicrornasasbiomarkersofals AT majidhafezparast overviewofmicrornasasbiomarkersofals |